<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The outcomes in adult B-cell <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) remain inferior to those achieved in pediatric populations </plain></SENT>
<SENT sid="1" pm="."><plain>Targeted therapy with monoclonal antibodies may improve outcomes in <z:e sem="disease" ids="C0279593" disease_type="Neoplastic Process" abbrv="">adult B-cell ALL</z:e> without significant additive toxicity </plain></SENT>
<SENT sid="2" pm="."><plain>Rituximab is the best known monoclonal antibody and is routinely used in combination chemo-immunotherapy for treatment of <z:e sem="disease" ids="C0279593" disease_type="Neoplastic Process" abbrv="">adult B-cell ALL</z:e> and Burkitts <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>A number of other monoclonal antibodies are currently under investigation for treatment of <z:e sem="disease" ids="C0279593" disease_type="Neoplastic Process" abbrv="">adult B-cell ALL</z:e> including unconjugated antibodies (eg., ofatumumab, alemtuzumab and epratuzumab), antibodies conjugated to cytotoxic agents (eg., inotuzumab ozogamycin and SAR3419), antibodies conjugated to toxins such Pseudomonas or Diptheria toxins (eg., BL22 and moxetumomab pasudotox), and T-cell engaging bi-specific antibodies that redirect cytotoxic T lymphocytes to lyse target ALL cells (eg., blinatumomab) </plain></SENT>
<SENT sid="4" pm="."><plain>In this article we review the therapeutic implications, current status and results of monoclonal antibody-based therapy in <z:e sem="disease" ids="C0279593" disease_type="Neoplastic Process" abbrv="">adult B-cell ALL</z:e> </plain></SENT>
</text></document>